LX-101 is under clinical development by Innostellar Biotherapeutics and currently in Phase II for Retinal Degeneration. According to GlobalData, Phase II drugs for Retinal Degeneration have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LX-101 overview
LX-101 is under investigation for the treatment of inherited retinal degeneration. It is administered through sub retinal route. It comprises of adeno associated virus 2 (AAV2) vector to deliver human retinal pigment epithelium 65 (RPE65) gene.
It was under development for Leber congenital amaurosis (LCA).
Innostellar Biotherapeutics overview
Innostellar Biotherapeutics (Innostellar) is a biopharmaceutical company specializes in focusing on drug discovery from gene therapy. Innostellar is headqurtered in Shanghai,China.
For a complete picture of LX-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
